Article Text

PDF
AB0939 Anti TNF therapy and malignancy in psoriatic arthritis and ankylosing spondylitis: The biosparegister
  1. K. de Vlam,
  2. I. Westhovens,
  3. P. Verschueren
  1. Rheumatology, University Hospitals Leuven, Leuven, Belgium

Abstract

Background Tumor necrosis factor alpha (TNF-a) is a key member of a large family of cytokines and receptors that are crucial to cellular organization. The development and use of biological therapy in the last several years, such as the TNF-a antagonists, has opened new perspectives for the treatment of patients with spondyloarthropathy (SpA). Nevertheless, it is now clear that TNF plays a paradoxical role in the evolution and treatment of malignant disease and the occurrence of malignancy has been considered as a possible adverse event in anti-TNF therapy.

Objectives To report systematically the malignancy incidence seen in a large cohort of patients with SpA treated with one or more anti-TNF therapies and to compare the results with the malignancy incidence in the global population.

Methods 231 patients with SpA that were treated with one or more anti-TNF therapies were included in a prospective observational cohort study for a total of 1199,83 patient years follow-up. The primary outcome for this study was the incidence of malignancy after starting anti-TNF treatment. Incidence rates were compared with the incidence rates of malignancy in Belgium by the Belgian Cancer Registry in the age group of 45-50 year old population in 2006.

Results In our study population, 6 out of 231 patients (2,6%) developed a malignancy after the start of anti-TNF treatment. The overall incidence rate of malignancy is 500,1 per 100000 patient years. Incidence rate for malignancy in female SpA patients is more than two-fold higher than that in males, but standardised incidence ratios are similar for male and female patients and indicate a higher incidence of malignancy in our study population compared to the control population

Conclusions Allthough there are certain study weaknesses, we can see a tendency towards a higher incidence of malignancy in SpA patients that are treated with anti-TNF therapy. It is still not clear whether this is a disease-related risk or a treatment-related risk.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.